1Mancini M,Hadchouel M,Davis HL, et al. DNA- mediated immunization in a transgenic mouse model of the hepatitis B surfase antigen chronic carrier state [J]. Proc Natl Acad Sci USA, 1996,93(22): 12496.
2Major ME, Vitvitski L, Mink MA, et al. DNA- based immunization with chimeric vectors for the induction of immune responses against the hepatitis C virus nucleocapsid []] .J Virol, 1995,69(9):5798.
3Cavanaugh VJ, Guidotti LG, Chisari FV, et al. Interleukin - 12 inhibits hepatitis B virus replication in transgenic mice [J] .J Virol,1997,71 (4): 3236.
4Guidotti LG, Ishikawa T, Hobbs MV, et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes [J ]. Immunity,1996,4(1) :25.
5Vitiello A, Ishioka G, Grey HM, et al. Development of a lipopeptide- based therapeutic vaccine to treat chronic HBV infection I. Induction of a primary cytotoxic T lymphocyte response in humans[J].J Clin Invest,1995,95(1):341.
6Bohjanen PR, Colvin RA, Puttaraju M, et al.A smallcircular TAR RNA decoy specifically inhabits Tat - activated HIV- 1 transcription [J]. Nucleic Acids Res, 1996,24(19) :2733.
8Alt M, Renz R, Hofschneider PH, et al. Core specific antisense phosphorothioate oligodeoxynucleotides as potent and specific inhabitor of hepatitis C viral translation [ J ]. Arch Virol, 1997, 142 (3): 589.
9Scaglioni P, Melegari M, Takahashi M,et al. Use of dominant negative nutants of the hepadnaviral core protein as antiviral agents [J].Hepatology, 1996,24 (5): 1010.
3Medley GF, Lindop NA, Edmunds WJ, et al. Hepatitis- B virus endemicity: hetero- geneity, catastrophic dynamics and contro| [J]. Nat Med, 2001, 7 (5): 619-624.
4Kurtenbach K, Hanincova K, Tsao JI, et al. Fundamental processes in the evolutionary ecology of Lyme borreliosis [ J ]. Nat Rev Microbiol, 2006, 4 (9): 660-669.
10Lai CI, Chien RN, Leung NW, et al. A one year trail of lamivudine for chronic hepatitis B Asia Hepatitis lamivudime study Group. NEngl J med, 1998,339:61 -68.
